BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 22445790)

  • 21. Inhibition of methyleugenol bioactivation by the herb-based constituent nevadensin and prediction of possible in vivo consequences using physiologically based kinetic modeling.
    Al-Subeihi AA; Alhusainy W; Paini A; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
    Food Chem Toxicol; 2013 Sep; 59():564-71. PubMed ID: 23831728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat.
    Al-Subeihi AA; Spenkelink B; Rachmawati N; Boersma MG; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
    Toxicol In Vitro; 2011 Feb; 25(1):267-85. PubMed ID: 20828604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.
    Al-Subeihi AA; Alhusainy W; Kiwamoto R; Spenkelink B; van Bladeren PJ; Rietjens IM; Punt A
    Toxicol Appl Pharmacol; 2015 Mar; 283(2):117-26. PubMed ID: 25549870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative in vitro kinetic study of [14C]-eugenol and [14C]-methyleugenol activation and detoxification in human, mouse, and rat liver and lung fractions.
    Minet EF; Daniela G; Meredith C; Massey ED
    Xenobiotica; 2012 May; 42(5):429-41. PubMed ID: 22188410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Interindividual Human Variation in Bioactivation and DNA Adduct Formation of Estragole in Liver Predicted by Physiologically Based Kinetic/Dynamic and Monte Carlo Modeling.
    Punt A; Paini A; Spenkelink A; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
    Chem Res Toxicol; 2016 Apr; 29(4):659-68. PubMed ID: 26952143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat.
    Al-Subeihi AA; Spenkelink B; Punt A; Boersma MG; van Bladeren PJ; Rietjens IM
    Toxicol Appl Pharmacol; 2012 May; 260(3):271-84. PubMed ID: 22445790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: example: methyleugenol, CASRN: 93-15-2.
    Smith B; Cadby P; Leblanc JC; Setzer RW
    Food Chem Toxicol; 2010 Jan; 48 Suppl 1():S89-97. PubMed ID: 20113858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk.
    Rietjens IM; Boersma MG; van der Woude H; Jeurissen SM; Schutte ME; Alink GM
    Mutat Res; 2005 Jul; 574(1-2):124-38. PubMed ID: 15914212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment.
    Rietjens IM; Punt A; Schilter B; Scholz G; Delatour T; van Bladeren PJ
    Mol Nutr Food Res; 2010 Feb; 54(2):195-207. PubMed ID: 19943261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constituents of aromatic plants: I. Methyleugenol.
    De Vincenzi M; Silano M; Stacchini P; Scazzocchio B
    Fitoterapia; 2000 Apr; 71(2):216-21. PubMed ID: 10727828
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.